Migraine is a prevalent and often debilitating condition that disproportionately affects women, particularly during their reproductive years. For the one in five women who suffer from migraine, finding effective treatment options that are safe during pregnancy remains a critical concern. Many commonly used migraine medications pose risks to the developing fetus, leaving patients and clinicians with limited, and sometimes inadequate, alternatives. CEFALY Technology’s participation at the American College of Obstetricians and Gynecologists (ACOG) 2025 Annual Clinical & Scientific Meeting underscores the urgency of addressing this unmet need by presenting a non-drug, clinically proven alternative for migraine relief.

The CEFALY device is an FDA-cleared neuromodulation system that delivers external trigeminal nerve stimulation (eTNS) through a non-invasive, wearable patch applied to the forehead. Designed for both acute migraine relief and preventative care, the device offers a novel mechanism of action by targeting the trigeminal nerve, a key pathway in migraine pathophysiology. This technology has shown promising results in reducing the frequency and intensity of migraine attacks and is particularly noteworthy for its potential use in pregnant patients. CEFALY’s ongoing pregnancy registry and educational outreach aim to build a robust evidence base for safe usage during pregnancy.

Through live demonstrations, educational programs, and clinician engagement at ACOG 2025, CEFALY is advancing its mission to provide accessible, safe, and drug-free migraine treatment options. By addressing a critical gap in migraine care—especially among pregnant women—CEFALY is promoting a shift toward non-pharmaceutical interventions in women’s health. As awareness grows and clinical data expands, the CEFALY device has the potential to become a vital tool for OB-GYNs and neurologists alike, offering improved quality of life for migraine sufferers across all stages of life.